Early stage (IA-IB) primary carcinoma of the fallopian tube: case-control comparison to adenocarcinoma of the ovary

被引:7
|
作者
Vaysse, Charlotte [1 ]
Touboul, Cyril [2 ]
Filleron, Thomas [3 ]
Mery, Eliane [4 ]
Jouve, Eva [5 ]
Leguevaque, Pierre [6 ]
Morice, Philippe
Leblanc, Eric [5 ]
Querleu, Denis [1 ]
机构
[1] Inst Claudius Regaud, Dept Surg, F-31052 Toulouse, France
[2] Inst Gustave Roussy, Dept Surg, Villejuif, France
[3] Inst Claudius Regaud, Dept Biostat, Toulouse, France
[4] Inst Claudius Regaud, Dept Pathol, Toulouse, France
[5] Ctr Oscar Lambret, Dept Surg, F-59020 Lille, France
[6] Hop Rangueil, Dept Surg, Toulouse, France
关键词
Fallopian tube carcinoma; Ovarian cancer; Early stage; Case-control study; PELVIC SEROUS CARCINOMA; INTRAEPITHELIAL CARCINOMA; CANCER; CHEMOTHERAPY; CISPLATIN; FIMBRIA;
D O I
10.3802/jgo.2011.22.1.9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Early stage primary carcinoma of the fallopian tube (PCFT) is an uncommon condition when strict criteria are applied. The aim of this study was to compare the outcome stage IA-IB PCFT to a matched group of ovarian cancer (OC). Methods: Between 1990 and 2008, 32 patients with stage IA-IB of PCFT were recorded in the database of three French Institutions. A control group of patients with OC was constituted. Results: Eleven eligible PCFT cases and 29 OC controls fulfilled the stringent inclusion criteria. Median follow-up was 70.2 months. Five-year overall survival was 83.3% (95% confidence interval [CI], 27.3 to 97.5) for PCFT and 88.0% (95% CI, 66.9 to 96.0) for OC (p=0.93). In the subgroup of patients with grade 2-3, the outcome was similar in PCFT compared to OC patients (p=0.75). Five-year relapse-free survival was respectively 62.5% (95% CI, 22.9 to 86.1) and 85.0% (95% CI, 64.6 to 94.2) in the PCFT and OC groups (p=0.07). In the subgroup of patients (grade 2-3), there was no difference between PCFT and OC (p=0.65). Conclusion: The findings did not reveal any difference in prognosis between early stage of PCFT and OC when grade is taken into account. Management of PCFT should mirror that of ovarian carcinoma.
引用
收藏
页码:9 / 17
页数:9
相关论文
共 13 条
  • [1] Serous fallopian tube carcinoma: A retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary
    Moore, Kathleen N.
    Moxley, Katherine M.
    Fader, Amanda Nickles
    Axtell, Allison E.
    Rocconi, Rodney P.
    Abaid, Lisa N.
    Cass, Ilana A.
    Rose, Peter G.
    Leath, Charles A., III
    Rutledge, Teresa
    Blankenship, Derek
    Gold, Michael A.
    GYNECOLOGIC ONCOLOGY, 2007, 107 (03) : 398 - 403
  • [2] Primary carcinoma of the fallopian tube and epithelial ovarian carcinoma - A case-control analysis
    Dunn, Melissa S.
    Manahan, Kelly J.
    Geisler, John P.
    JOURNAL OF REPRODUCTIVE MEDICINE, 2008, 53 (09) : 691 - 694
  • [3] Comparison of early-stage primary serous fallopian tube carcinomas and equivalent stage serous epithelial ovarian carcinomas
    Horng, Huann-Cheng
    Lai, Chiung-Ru
    Chang, Wen-Hsun
    Wen, Kuo-Chang
    Chen, Yi-Jen
    Juang, Chi-Mou
    Yen, Ming-Shyen
    Wang, Peng-Hui
    Taiwanese Journal of Obstetrics & Gynecology, 2014, 53 (04): : 547 - 551
  • [4] Management of advanced-stage primary carcinoma of the fallopian tube: case report and literature review
    Kuscu, E
    Oktem, M
    Haberal, A
    Erkanli, S
    Bilezikci, B
    Demirhan, B
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2003, 24 (06) : 557 - 560
  • [5] Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review
    Hirte, Hal
    Yao, Xiaomei
    Ferguson, Sarah E.
    May, Taymaa
    Elit, Laurie
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 162
  • [6] Clinicopathologic Evaluation and Molecular Profiling of Recurrent Stage IA Endometrial Endometrioid Carcinoma: A Case-control Study
    Sharma, Aarti E.
    Moran, Angelica
    Somasegar, Sahana
    Steinhardt, George
    Chapel, David B.
    Lastra, Ricardo R.
    Lee, Nita K. K.
    Ritterhouse, Lauren L.
    Bennett, Jennifer A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2023, 42 (01) : 26 - 34
  • [7] Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II-IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline
    Hirte, Hal
    Poon, Raymond
    Yao, Xiaomei
    May, Taymaa
    Ethier, Josee-Lyne
    Petz, Lauri
    Speakman, Jane
    Elit, Laurie
    CURRENT ONCOLOGY, 2022, 29 (01) : 231 - 242
  • [8] Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II-IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review
    Hirte, Hal
    Poon, Raymond
    Yao, Xiaomei
    May, Taymaa
    Ethier, Josee-Lyne
    Petz, Lauri
    Speakman, Jane
    Elit, Laurie
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 162
  • [9] Prognostic indicators in patients with early stage endometrioid adenocarcinoma: a retrospective case-control study of 523 patients
    Zou, Shien
    Sun, Hong
    Fan, Lingling
    Xiao, Xirong
    Gong, Lili
    Zhu, Jin
    Chen, Xing
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (02): : 3692 - 3698
  • [10] Central pancreatectomy for early-stage pancreatic ductal adenocarcinoma: a single-center case-control study
    Gao, Hao
    Liu, Tongtai
    Wang, Guangfu
    Gao, Yong
    Yin, Lingdi
    Peng, Yunpeng
    Lyu, Nan
    Zhang, Kai
    Gao, Wentao
    Wu, Junli
    Jiang, Kuirong
    Wei, Jishu
    Miao, Yi
    LANGENBECKS ARCHIVES OF SURGERY, 2019, 404 (02) : 175 - 182